BioCryst Pharma Receives Positive Opinion From EU For Angiodema Compound BCX4161

(RTTNews) - BioCryst Pharmaceuticals, Inc., (BCRX) Wednesday said received a positive opinion from Committee for Orphan Medicinal Products of the European Medicines Agency for its BCX4161, intended for treatment of hereditary angioedema. The commission will decide on Orphan Drug status of the compound later, the company noted.

BCX4161 is a selective inhibitor of plasma kallikrein in development, that suppresses bradykinin, for prevention of rapid and acute swelling in dermis.

On December 23, the company has received orphan drug designation for BCX4161 from FDA.